Skip to main content
. 2017 May 15;7:94. doi: 10.3389/fonc.2017.00094

Figure 2.

Figure 2

Sensitive PDX models treated to acquired resistance to ENMD-2076 treatment. (A) Tumor growth curves for PDX models CU_TNBC_002 and CU_TNBC_005 depicting individual ENMD-2076 treated tumors and vehicle controls selected for immunohistochemistry (IHC), IF, and genomic analysis. Acquired resistance was defined as a doubling in tumor volume from day 30 while receiving ENMD-2076 treatment. (B) % change from baseline for the selected tumors selected for acquired resistance in panel (A). Arrows indicate acquired resistance tumors. (C) CU_TNBC_002 and (D) CU_TNBC_005 tumor samples obtained from vehicle, ENMD-2076 treated sensitive at day 30, and ENMD-2076 treated acquired resistance stained for hematoxylin/eosin (H&E), Ki67, and CD34. (E) CU_TNBC_004 tumor samples obtained from vehicle and ENMD-2076 treated at day 30. Representative images were taken using a Zeiss microscope at 10× magnification. Scale = 10 µm. EOS, end of study.